15e28 days and 29e180 days. Primary outcome was 30-days combined stroke and death rate. Results: In total 269 patients had complete data and were included in the analysis. The demographic and clinical data were similar in the groups The 30-day combined stroke and death rate did not differ significantly between the groups; 0% (0/12) in the group treated 0e 2 days, versus 3.9% (3/76), 2.9% (2/68), and 5.3% (6/113) for the patients treated at 3e7 days, 8e14 days and 15e180 days respectively (p ¼ 0.759). The 30-day stroke and death rate in the secondary analysis were also similar between groups; 3.4% (3/88), 2.9% (2/68), 6.3% (3/48), and 4.6% (3/65) respectively, (p ¼ 0.813). Conclusion: In this national registry study, limited by small numbers, patients that underwent urgent CAS after onset of a neurologic event had no additional risk of suffering from a perioperative complication.
Introduction: When a Boeing aircraft develops a problem at New York, within the next 24 hrs the whole Boeing fleet, the world over, gets an alert with initial defect report, cause and a fix. On the other hand when the trigger mechanism of delivery system of an SFA stent fails in a London Hospital, nothing similar happens. FDA mandates the manufacturers to report all adverse events within 30 days on the MUADE database. An analysis of 500 adverse event reports on SFA stents reveals lessons for the vascular societies and calls for unified action for the sake of patient safety. Methods: MAUDE database was searched for all adverse event reports on SFA stents from 01/04/2012 to 31/03/2014. Each report lists the event description, the date, patient injury, intervention if required and the manufacturer's narrative. Results: 500 SFA stent adverse reports were recorded and analysed. All known manufacturers were listed. Adverse reports from 2 stent manufacturers were significantly more than the others. A similar deployment failure was reported for over 1 year by one manufacturer. More than 1/3rd of the reported cases had either a failure in deployment of the stent or retrieval of the standard delivery system (sds). In another 1/3rd the stent was damaged after deployment-twisted, torqued, fractured, or occluded. In the remaining 1/3rd there were multitudes of problems from breakage of sds components and their retention within the patient to dislodgment.
Adverse patient effects included Acute Limb ischemia, limb loss and death. Majority required endovascular intervention, failing which an open procedure was performed in 20% of patients.
Analysis of manufacturer's narrative rarely revealed no attributable cause, the malfunction, mal-deployment was labeled as procedure related and not device related. The manufacturer's narrative often stated that the device met pre-release specifications and no manufacturing defect could be identified. Conclusion: A review of adverse event reports form manufacturer's clearly indicates that the adverse event was procedure related and probably due to the operator not exercising due care or not following the IFU. There is a need for the societies to take a lead in user adverse event reporting, analysis and communicating these to the centre's on a definitive time scale in a more open and unified manner to prevent patient harm and improve outcomes. Introduction: Spinal cord ischemia (SCI) is a devastating complication following thoracoabdominal aortic aneurysm (TAAA) endovascular repair. In an attempt to reduce its occurrence, we have modified our implantation protocol in January 2010 by withdrawing all large sheaths from the iliac arteries as soon as possible during the procedure. In addition, we have also modified our perioperative protocol (aggressive blood and platelet transfusion, median arterial pressure monitoring >80 mmHg, and systematic cerebrospinal fluid drainage except for type 4 TAAA). Methods: Between October 2004 and December 2013, we have performed 204 TAAA endovascular repairs with custom made devices manufactured with branches and fenestrations to perfuse the visceral vessels. Data from all patients were prospectively collected in an electronic database. We compared the early outcomes of patients treated before (group 1, 43 patients) and after (group 2, 161 patients) modification of our implantation and perioperative protocols. Introduction: Reports of thoracic endovascular aortic repair (TEVAR) for complicated acute type B dissection bring together a large range of clinical presentations. With a 50% of 30-day mortality rate when managed with open surgery, rupture is the most dramatic complication of acute type B dissections. We investigated the outcomes of TEVAR for acute type B dissection complicated by rupture (R-ABD) to assess the results of this particularly critical subgroup. Methods: A review of consecutive TEVAR for R-ABD in two tertiary centers was performed using prospectively maintained database. Results: Between 2000 and 2014, 24 patients (mean age 68 years; 14 males) underwent TEVAR for R-ABD. Sixteen (67%) were in shock (Systolic blood pressure <80 mmHg) before surgery and 20 required chest drainage for hemothorax. Proximal entry tear was in zone 2 in 7 (29%) and 3 in 17 (71%). Five patients required coverage of the left subclavian artery for adequate proximal landing zone, of whom 3 with concomitant extra-anatomic debranching of the supra-aortic vessels. Technical success was achieved in 100%. The 30-day mortality rate was 16.7% (n ¼ 4). Two patients had paraplegia. Neither stroke nor renal insufficiency requiring new dialysis occurred. During a mean follow-up of 28 months, another death in relation with dissection occurred and 8 patients (33%) required reintervention. All reintervention were managed by endovascular means. At last follow up CT-scan, 8 patients (33%) had complete remodeling of the aortic wall. Conclusion: This study confirms the feasibility of TEVAR for R-BAD and its lower perioperative morbidity and mortality rate compared to open surgery, reducing by more than 2 third the 30-day mortality. However the rate of reintervention is high and a long term follow up is mandatory. Introduction: Dipeptidyl peptidase-4 inhibitor alogliptin has been proved to prevent abdominal aortic aneurysm (AAA) formation. However, the mechanism of alogliptin on aneurysm development has not been sufficiently investigated. The objective of this study was to determine how alogliptin prevents further dilation of AAA development mimicking clinical setting. Methods: The AAA model induced with intraluminal elastase and extraluminal calcium chloride was created in 42 rats. Forty-two rats were divided 3 groups: a low-dose of alogliptin group (Group LD; 1 mg/kg/day), a high-dose group (Group HD; 3 mg/kg/day), and a control group (Group C, water). Alogliptin administration by gastric gavage once per day was started on 7 days after aneurysm formation (Dilatation ratio: 158.9 AE 7.7%). On day 14, reactive oxygen species (ROS) expression and the oxidation product of DNA 8-hydroxydeoxyguanosine (8-OHdG) was measured. As ROS have been reported to activate ERK pathway which is important modulator of MMPs and inflammatory cytokines, MMP expression and inflammatory response were also analyzed along with ERK evaluation. Histopathological examination was performed on day 28, and the AAA dilatation ratio was calculated to evaluate alogliptin protective effect. Results: On day 14, ROS expression and 8-OHdG positive cells in aneurysm walls were decreased by alogliptin treatment (ROS expression: 4.4 AE 0.6 in Group C, 3.2 AE 0.1 in Group LD, and 2.7 AE 0.3 in Group HD, p < 0.001; 8-OHdG-positive cells: 167.4 AE 6.9 cells in Group C, 102.7 AE 19.9 cells in Group LD, and 64.7 AE 2.7 cells in Group HD, p < 0.001). Western blot analysis showed decrease ERK levels in treatment groups compared with in control group. The treatment significantly reduced mRNA expression of MMPs, TNF-a and MCP-1 in aneurysm walls. Immunohistochemical staining for CD68 demonstrated the decrease of macrophage infiltration in aneurysm wall with treatment groups. On day 28, the aortic wall in groups LD and HD were less dilated, and had higher elastin content than those in Group C (Dilatation ratio: 199.2 AE 10.8% in Group C, 170.0 AE 4.4% in Group LD, and 155.1 AE 2.3% in Group HD, p < 0.001). Conclusion: Alogliptin treatment starting after aneurysm formation inhibits further dilation in rat model through anti-oxidant and anti-inflammatory effect. Inhibition of ERK activation by reducing oxidative stress prevented inflammatory response and matrix degeneration, resulting in prevention of the aortic dilatation. Introduction: Ipsilateral, single segment great saphenous vein (GSV) remains the optimal conduit for below knee bypass to treat critical limb ischemia. There is a need to better define the benefit of alternative autologous vein (AAV) segments over contemporary prosthetic conduits in patients in whom GSV is not available. Methods: Patients who underwent bypass to below-knee targets for chronic arterial occlusive disease between 2007e2011 were retrospectively reviewed and categorized in three groups: GSV; AAV (small saphenous veins, arm veins or spliced vein segments); Prosthetic. The primary outcome was graft patency (primary, assisted primary, secondary). Secondary outcome was limb salvage. Cox regression models were used to assess the effect of baseline predictors. Results were considered statistically significant when p-value was <0.05.
